Thyrocare Technologies growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+20.6%+16.3%
EBITDA+37.7%+29.7%
Net Income+79.5%+36.3%
EPS (adj.)+78.2%+36.2%
Total Assets+7.9%+5.7%
Total Equity+7.1%+3.1%
Free Cash Flow+31.4%+30.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THYROCARE₹515.50

Thyrocare Technologies Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹8,205 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+20.6+16.3
EBITDA+37.7+29.7
Net Income+79.5+36.3
EPS (adj.)+78.2+36.2
Total Assets+7.9+5.7
Total Equity+7.1+3.1
Free Cash Flow+31.4+30.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.